Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Most blood cancer patients face uphill battles just to get their oral medications. A new nationwide study found that insurers initially rejected 65% of Medicare and 84% of commercial prescriptions for specialty oral anticancer drugs — and even after approval, nearly half of patients never filled them, largely due to high out-of-pocket costs.
Getting a blood cancer prescription is one thing — actually receiving the medication is another. A new study published in the Journal of Clinical Oncology analyzed over 12,000 patients newly prescribed specialty oral anticancer medications (SOAMs) for leukemias, lymphomas, or myeloma, and found that insurance barriers are blocking access at nearly every step.
Initially, insurers rejected 64.9% of Medicare prescriptions and 84% of commercial ones. The most common reasons: prior authorization requirements, formulary exclusions, and quantity limits. While most rejections were eventually overturned — approval rates climbed to 85% for Medicare and 62.8% for commercial patients within 90 days — the delays create real harm, consuming staff resources and distressing patients. Even among those who got the green light, only 54.5% of Medicare and 45.5% of commercially insured patients actually filled their prescriptions.
By the Numbers:
Why it matters: These findings highlight a system where administrative hurdles and cost burdens — not clinical need — determine who gets life-saving cancer therapy. Professional societies like ASCO and ASH are calling for reform to improve utilization management practices and patient affordability.
